BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 18316823)

  • 1. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    Bertrand OF; Faurie B; Larose E; Nguyen CM; Gleeton O; Déry JP; Noël B; Proulx G; Roy L; Costerousse O; De Larochellière R; Rodés-Cabau J
    J Invasive Cardiol; 2008 Mar; 20(3):99-104. PubMed ID: 18316823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Marzocchi A; Saia F; Piovaccari G; Manari A; Aurier E; Benassi A; Cremonesi A; Percoco G; Varani E; Magnavacchi P; Guastaroba P; Grilli R; Maresta A
    Circulation; 2007 Jun; 115(25):3181-8. PubMed ID: 17562952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study).
    Harjai KJ; Orshaw P; Shenoy C; Acharji S; Sporn D; Aboufares A; Stapleton D
    J Interv Cardiol; 2008 Aug; 21(4):315-24. PubMed ID: 18754967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.
    Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Slottow TL; Xue Z; Torguson R; Kaneshige K; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):496-500. PubMed ID: 19195509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
    Qasim A; Cosgrave J; Latib A; Colombo A
    Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term results of unprotected left main percutaneous coronary intervention with DES versus BMS.
    Capodanno D; Di Salvo ME; Capranzano P; Seminara D; Caggegi A; Barrano G; Tamburino C
    Minerva Cardioangiol; 2009 Feb; 57(1):1-6. PubMed ID: 19202514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of drug eluting stents with bare metal stents in daily practice for bifurcation lesions in Chinese patients.
    Kang S; Yang YJ; Xu B; Chen JL; Qiao SB; Yao M; Chen J; Wu YJ; Liu HB; Dai J; Yuan JQ; Li JJ; Gao RL
    Chin Med J (Engl); 2006 Jul; 119(14):1157-64. PubMed ID: 16863606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings.
    Harjai KJ; Orshaw P; Boura J; Sporn D
    Am J Cardiol; 2009 Jun; 103(11):1537-45. PubMed ID: 19463512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
    Bavry AA; Kumbhani DJ; Helton TJ; Bhatt DL
    J Am Coll Cardiol; 2005 Mar; 45(6):941-6. PubMed ID: 15766833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry.
    Dou KF; Xu B; Yang YJ; Chen JL; Qiao SB; Li JJ; Qin XW; Liu HB; Wu YJ; Chen J; Yao M; You SJ; Yuan JQ; Dai J; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):612-6. PubMed ID: 19323921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry.
    Abbott JD; Voss MR; Nakamura M; Cohen HA; Selzer F; Kip KE; Vlachos HA; Wilensky RL; Williams DO
    J Am Coll Cardiol; 2007 Nov; 50(21):2029-36. PubMed ID: 18021868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting compared with bare-metal coronary stents among elderly patients.
    Groeneveld PW; Matta MA; Greenhut AP; Yang F
    J Am Coll Cardiol; 2008 May; 51(21):2017-24. PubMed ID: 18498954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
    Yan BP; Ajani AE; New G; Duffy SJ; Farouque O; Shaw J; Sebastian M; Lew R; Brennan A; Andrianopoulos N; Reid C; Clark DJ;
    Int J Cardiol; 2008 Nov; 130(3):374-9. PubMed ID: 18706719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent.
    Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF
    Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.